Last updated: 11/04/2018 06:04:09

A study to investigate the effects of GW876008 on brain activation during emotional processing in healthy subjects.

GSK study ID
CRH104150
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A randomized, placebo-controlled, double-dummy, four-way crossover design study to investigate the changes of fMRI BOLD activation induced by emotional activation paradigms following single doses of GW876008 and lorazepam (comparator) in healthy subjects.
Trial description: Data suggests that imaging activity of the brain can measure the effects of anti-anxiety drugs. This study will investigate the effect of GW876008 on areas of the brain involved with thinking and emotion
Primary purpose:
Diagnostic
Trial design:
Crossover Assignment
Masking:
Not applicable
Allocation:
Randomized
Primary outcomes:
Not applicable
Secondary outcomes:

GW876008 blood levels

Timeframe: pre-dose & post-dose, sessions 1-4

clinical rating scales change after dosing: questionnaires collected

Timeframe: pre-dose & up to 6-8 hours post-dose.

Interventions:
  • Drug: placebo
  • Drug: lorazepam
  • Drug: GW876008
  • Enrollment:
    26
    Primary completion date:
    Not applicable
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Healthy Subjects
    Product
    emicerfont, lorazepam
    Collaborators
    Not applicable
    Study date(s)
    March 2007 to December 2007
    Type
    Interventional
    Phase
    1

    Participation criteria

    Sex
    Female & Male
    Age
    18 - 50 Years
    Accepts healthy volunteers
    Yes
    • Healthy males or females aged 18-50 years, inclusive.
    • STAI-trait score = or > 40.
    • As a result of any of the medical interview, physical examination, evaluation of mental state and psychiatric history or screening investigations the physician responsible considers the subject unfit for the study.
    • Any history of suicidal attempts or behaviour.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    La Jolla, California, United States, 92093
    Status
    Study Complete

    Study documents

    No study documents available.

    Results overview

    Study Results yet to be posted

    Recruitment status
    Study complete
    Actual primary completion date
    Not applicable
    Actual study completion date
    2007-19-12

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website